Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer
International Journal of Molecular Sciences · 18.10.2024 · 25 (20) · 11214
DOI: 10.3390/ijms252011214 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.10.2024. Verfasst von Nicoletta Cordani und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proteolysis, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains a disease with a poor prognosis despite the advances in therapies. NSCLC with actionable oncogenic alterations represent a subgroup of diseases for which tyrosine kinase inhibitors (TKIs) have shown relevant and robust impact on prognosis, both in early and advanced stages. While the introduction of powerful TKIs increases the ratio of potentially curable patients, the disease does develop resistance over time through either secondary mutations or bypass activating tracks. Therefore, new treatment strategies are being developed to either overcome this inevitable resistance or to prevent it, and proteolysis targeting chimera agents (PROTACs) are among them. They consist of two linked molecules that bind to a target protein and an E3 ubiquitin ligase that causes ubiquitination and degradation of proteins of interest. In this paper, we review the rationale for PROTAC therapy and the current development of PROTACs for oncogene-addicted lung cancer. Moreover, we critically analyze the strengths and limitations of this promising technique that may help pave the way for future perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
- Medical Oncology Unit, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) San Gerardo dei Tintori, 20900 Monza, Italy.
ORCID-Profile: Nicoletta Cordani, Luca Sala, Diego Luigi Cortinovis
Zitieren
APA
Cordani, N., Nova, D., Sala, L., Abbate, M. I., Colonese, F., Cortinovis, D. L., & Canova, S. (2024). Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 25(20), 11214. https://doi.org/10.3390/ijms252011214
Vancouver
Cordani N, Nova D, Sala L, Abbate MI, Colonese F, Cortinovis DL, et al. Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2024;25(20):11214. doi:10.3390/ijms252011214
BibTeX
@article{Cordani2024,
author = {Cordani, Nicoletta and Nova, Daniele and Sala, Luca and Abbate, Maria Ida and Colonese, Francesca and Cortinovis, Diego Luigi and Canova, Stefania},
title = {Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {20},
pages = {11214},
doi = {10.3390/ijms252011214}
}
EUVIMED